Table 3. Frequency and chromosomal localization of recurrently amplified genes (> 5% of cases) in GBM from series 1 (n=45/80 tumors), and other previously reported series of GBM (n=111/267 tumors) as detected by SNP-arrays.
| Amplified genes | |||||
|---|---|---|---|---|---|
| Amplified chromosomal regions | Symbol | Frequency of gene amplification | |||
| Chr | Amplified/Total cases (%) |
Cytoband | Series 1 (n=45) |
Series 2-8 (n=111) |
|
| Chr 7 | 119/347 (34%) |
7p11.2 |
EGFR LANCL2 VSTM2A VOPP1 SEC61G |
67% 40% 31% 27% 11% |
57% 19% 29% 7% 19% |
| 12q14.1 |
CDK4 CYP27B1 METTL1 AVIL CTDSP2 METT21B AGAP2 OS9 TSFM |
29% 29% 27% 27% 27% 22% 22% 16% 16% |
14%* 2%* 14%* 18%* 2%* 16%* 16%* 2%* - |
||
| Chr 12 | 34/347 (10%) |
12q13.3 |
B4GALNT1 KIF5A PIP4K2C SLC26A10# DTX3 MARS ARHGEF25 DCTN2# |
16% 11% 11% 11% 9% 9% 9% 7% |
14%* 10%* - - 12%* 4%* 4%* - |
| 12q15 |
ATP23 MDM2 CPM |
16% 9% 9% |
14%* 12% 11% |
||
| Chr 4 | 26/347 (7%) |
4q12 |
SCFD2 FIP1L1 PDGFRA KIT |
18% 18% 18% 7% |
7% 14% 10% 10% |
| Chr 1 | 14/347 (4%) |
1q32.1 |
SOX13 ETNK2 REN KISS1 GOLT1A PLEKHA6 PIK3C2B MDM4 LRRN2 |
11% 11% 11% 11% 11% 11% 11% 11% 9% |
5% 3% 2% 3% 3% 5% 5% 3% 2% |
#genes included in the SNP6 array; *The incidence of amplified genes localized in the 12q14.1, 12q13.3 and 12q15 cytobands was calculated using only the 250k-SNP_Nsp and/or STY arrays (n=50) due to the absence of probes for these specific genes in the 50k array.